

Review Article

Insights into the Roles of B Cells in Patients with Sepsis

Xijie Dong ¹, Hao Tu ¹, Shuang Qin ², Xiangjun Bai ¹, Fan Yang ¹, and Zhanfei Li ¹

¹Trauma Center/Department of Emergency and Traumatic Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

²Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Fan Yang; whjt_yf@163.com and Zhanfei Li; whjt_lzf@163.com

Received 11 February 2023; Revised 2 April 2023; Accepted 4 April 2023; Published 22 April 2023

Academic Editor: Lalit Batra

Copyright © 2023 Xijie Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis is a life-threatening yet common disease, still posing high mortality worldwide. Sepsis-related deaths primarily occur during immunosuppression; the disease can hamper the numbers and function of B cells, which mediate innate and adaptive immune responses to maintain immune homeostasis. Dysfunction of B cells, along with aggravated immunosuppression, are closely related to poor prognosis. However, B cells in patients with sepsis have garnered little attention. This article focuses on the significance of B-cell subsets, including regulatory B cells, in sepsis and how the counts and function of circulating B cells are affected in patients with sepsis. Finally, potential B-cell-related immunotherapies for sepsis are explored.

1. Introduction

Sepsis is a complex disease. Although its etiology has been most recently defined as “a dysregulated host response to infection” [1], different patients may have prior exposure to different pathological processes, such as trauma, burns, or acute abdomen [2]. Also, the pathogens that cause such infections may vary, such as bacteria, viruses, or fungi [3]. Historically adopted etiological therapies primarily focused on the removal or drainage of the infectious foci and the use of antibiotics. Current approaches also pay attention to helping patients recover normal immune function [4, 5].

Patients with sepsis experience immune disorders that can be divided into two processes: pro-inflammatory response and immunosuppression, which occur sequentially or simultaneously [6]. Advances in medical care have helped most patients with sepsis survive pro-inflammatory outbreaks; deaths in patients with sepsis occur mainly during immunosuppression [7, 8]. Immunosuppression is an important cause of late death in early survivors of sepsis and remains difficult to treat [9, 10]. Many studies have shown that lymphocyte failure contributes to immunosuppression in sepsis [2, 4, 10].

B cells are an important subset of lymphocytes that mediate adaptive and innate immune responses by producing antibodies,

presenting antigens, and secreting cytokines [11, 12]. They are also able to interact with other innate and adaptive immune cells and affect each other's function during sepsis and inflammation [13–15]. Although B cells are the foundation of immune homeostasis, and B-cell failure will inevitably trigger or exacerbate immunosuppression [4, 16], most studies have focused on how other immune cells change during sepsis while neglecting B cells. B cells play a more important role in sepsis than previously thought [17]; for example, both pathogen clearance and survival were reduced in B-cell-deficient septic mice, and supplemental B cells improved the survival rates of Rag1-deficient mice [18]. Other studies conducted in patients with sepsis or septic shock have associated peripheral blood B-cell depletion and decreased serum IgM levels with poor prognosis. Relieving B-cell depletion and alleviating the decrease of IgM levels likely reduce immunosuppression and improve patient outcomes [19–21]. Clarifying the mechanisms of B-cell immunity in sepsis is prerequisite to developing immunotherapies that can successfully treat immunosuppression.

2. The Development and Activation of B Cells

Bone marrow serves as the primary location for B-cell growth and storage. Here, hematopoietic stem cells give




FIGURE 1: Development and differentiation of B-cell lineage. B cells originate from progenitors that derive from stem cells and undergo multiple developmental stages, with the B1 subset from fetal liver and the B2 subset from bone marrow. The B1 subset is composed of B-1a and B-1b subsets, and the B2 subset is comprised of marginal zone (MZ) and follicular (FO) B cells. The B1 subset and MZ B cells belong to the innate B cells that can be activated independently of T cells and differentiate rapidly into short-lived plasmablasts, which produce low-affinity antibodies without entering the germinal center (GC). On the other hand, FO B cells can interact with activated naive T cells at the T–B border. If the interaction is insufficient, activated B cells differentiate into short-lived plasmablasts that produce low-affinity antibodies. However, if the interaction is sufficient, they can also differentiate into GC B cells. GCs are composed of dark and light zones, and high-affinity clones eventually exit the GCs and differentiate into memory B cells and long-lived plasma cells that secrete high-affinity antibodies. Tfh, follicular helper T. FDC, follicular dendritic cell.

rise to diverse B-cell lineages, which then move through various developmental phases, such as pro-B cells, pre-B cells, and immature B cells [22–24]. Most immature B cells leave the bone marrow after their heavy and light-chain immunoglobulin (germline) genes rearrange to form the fully functional B-cell receptor (BCR) and completely differentiate in the periphery to form transitional B cells [24, 25]. Most of these cells are self-tolerant, with few autoreactive cells that undergo clonal deletion or receptor editing in the periphery and eventually develop into naïve B cells [24, 26, 27]. Naïve B cells circulate in the peripheral blood and lymphoid tissues, continue to activate and differentiate when they encounter a

homologous antigen, and die within a few days if they do not encounter the homologous antigen [28].

Naïve B cells can be divided into two groups: B1 and B2 cells (Figure 1). The former consists of B-1a and B-1b subsets, and the latter consists of marginal zone (MZ) and follicular (FO) B cells [29]. Mature B cells migrate to peripheral lymphoid tissue and can become active when encountering homologous antigens in a sepsis setting. Their activation response can be divided into two distinct pathways that occur in the absence or presence of T-cell help, respectively.

In general, B1 and MZ B cells are activated independently of helper T cell (Th) help. They can rapidly differentiate into

short-lived plasmablasts without entering the germinal center (GC) to quickly build the body's first line of defense against infection before FO B cells play a role [30–33]. In response to bacterial components, MZ B cells exhibit a high sensitivity and are capable of producing antibodies swiftly and sustainably [34]. Further, they can secrete IL-6, as well as CXCL1/CXCL2, within 3–4 hr following *Staphylococcus aureus* infection, contributing to the recruitment of neutrophils to the site of infection, thereby facilitating the speedy elimination of invading pathogens [35]. B-1a cells, on the other hand, are noted for secreting natural IgM and IgG3 to neutralize endotoxins, thereby playing a crucial role in purging pathogenic substances from circulation and improving sepsis [36].

FO B cells become active when the BCR recognizes antigens and key helper signals from antigen-specific Th cells. The antigen binds to the BCR and triggers the necessary gene expression program in the cell, which then leads to T–B-cell interactions through the expression of multiple chemokine receptors and corresponding ligands. If the interaction is insufficient, activated B cells do not enter the GC but develop into extrafollicular plasma cells, producing mainly IgM immunoglobulins that coordinate innate immunity and initiate GC responses. If the interaction is sufficient, the activated B cells return to lymphatic follicles for rapid cloning and expansion to form GC (Figure 1). Centroblasts divide to form centrocytes, migrate outward from the dark zone to form the light zone, interact with dendritic cells and follicular helper T (T_{fh}) cells, then differentiate into memory B cells and plasmablasts [30, 37–40]. In septic mice, T_{fh} cells have been shown to help prevent the depletion of FO B cells [41].

3. The Significance of B Cells in Sepsis

FO B cells, conventional B cells in the adaptive immune system, are the most numerous of all B-cell lineages. Although FO B cells also participate in T-cell-independent (TI) IgM responses, they are mainly differentiated with the help of T lymphocytes into long-lived plasma cells and class-switched memory B cells that produce high-affinity IgG antibodies and mediate the classical humoral immune response [30]. Long-lived plasma cells consistently produce high-affinity antibodies, and although they do not express antigen receptors and cannot sense antigens, they continue to release their products as high-affinity antibody factories as the first line of defense against reinfection [42–44]. Class-switched memory B cells express specific antigen receptors that trigger a memory response when the antigen is encountered again. During reinfection, memory B cells rapidly differentiate and continue to supply high-affinity antibodies to the blood at the level of existing antibodies, effectively preventing antigen challenge [45]. Secondary infections are less likely to occur due to immune memory or even at all in healthy individuals [44]. However, many memory B cells are depleted in patients with sepsis, hindering humoral immunity and therefore increasing the risk of secondary infection. Indeed, depletion of memory B cells and low antibody levels are closely related to poor patient outcomes, suggesting that an intact humoral immune response is important in sepsis [46–49].

The onset of the FO B-cell-mediated adaptive immune response develops at least 5–7 days after the initial infection. This delay can be fatal if blood or mucosal infection occurs before this time. B1 cells and MZ B cells compensate for this limitation, as they mediate an innate immune response by producing IgM, IgG, and IgA antibodies through a faster TI pathway [32, 50]. B1 cells can not only respond to some TI antigens but also recognize the surface antigens of some Gram-negative bacteria. They can either manage infection by secreting antibodies mainly composed of low-affinity IgM or govern intestinal defense against pathogens by secreting IgA. Moreover, B1 cells can enter the GC for class switching and somatic hypermutation when self-regulation is disordered and produce high-affinity IgG antibodies [51–53]. Remarkably, B-1a cells have reduced excessive inflammation during sepsis by producing large amounts of IL-10 and granulocyte-macrophage colony-stimulating factor in a mouse model of sepsis [54–56]. Studies have also shown that mice with bacterial sepsis have significantly fewer B-1a cells, and B-1a cell-deficient mice are more prone to infection and death. Supplemental B-1a cells can significantly reduce systemic inflammation and improve the survival rates of septic mice [57].

Like B1 cells, MZ B cells can quickly respond to some TI antigens, secrete the first wave of innate immune response antibodies, and modulate the function of T cells and dendritic cells by secreting various cytokines. MZ B cells help regulate rapid systemic anti-infective immunity in host defense responses, dominating the early stages of pathogen eradication [58, 59]. Mice lacking MZ B cells produce fewer antibodies in the early stages after pathogens invade circulation [60, 61]. In addition, MZ B cells can connect the innate immune system and adaptive immune system by initiating low-affinity antibody responses, and they cooperate with lymphocytes and antigen-presenting cells in T-cell-dependent and TI immune responses [62, 63]. Of note, the role of MZ B cells in the inflammatory response remains controversial [64, 65]. On the one hand, MZ B cells can secrete pro-inflammatory cytokines such as IL-6 and C-C motif chemokine ligand 2, which exacerbate the inflammatory response [66]. Pro-inflammatory cytokines produced by MZ B cells can aggravate lipopolysaccharide (LPS)-induced systemic inflammatory responses, and mice lacking MZ B cells are resistant to LPS-induced endotoxic shock [64]. On the other hand, MZ B cells may suppress inflammatory responses during the early stages of infection by producing IL-6, which inhibits the production of tumor necrosis factor- α and, therefore, the systemic inflammatory response [67]. MZ B cells are also the cells with the strongest ability to produce inflammatory inhibitory factor IL-10 in vitro [68].

Collectively, the adaptive and innate immune functions of B cells play an important role in sepsis, and the two aspects are closely related. While the abundance of high-affinity antibodies secreted during the adaptive immune response is essential to fighting infection, the role of the innate immune response should not be underestimated [22]. It is well established that sepsis can cause abnormalities in the counts and functions of B cells [16]. These abnormalities, in turn, inevitably lead to impaired immune functions mediated by B cells, resulting in an inability to effectively stifle the attack of

pathogens, weakening the protective effect on the body and exacerbating the deterioration of sepsis.

4. Regulatory B Cells in Sepsis

Regulatory B cells (Bregs) are a specialized subset of B cells with immunomodulatory functions. The precise source of Bregs remains unknown, however, it has been observed that nearly all subsets of B cells can differentiate into Bregs [69]. They play an important role in maintaining immune homeostasis and tolerance by producing anti-inflammatory cytokines and suppressing inflammatory responses [70].

Breg counts are disturbed in sepsis. Umakoshi et al. [71] found the frequency of CD1d⁺CD5⁺ Bregs in the peripheral blood of cecum ligation and puncture mice increased at 6 hr and returned to baseline at 7 days. The emergence of Bregs accompanied by B lymphocytopenia was the first observable event in sepsis, potentially resulting in immunoparalysis. In a mouse model of endotoxic shock, it was observed that the percentage of CD5⁺CD1d^{hi} Bregs decreased. Transfer of CD5⁺CD1d^{hi} Bregs from healthy wild-type (WT) mice offered protection against severe endotoxic shock [72]. In patients with sepsis, the percentage of IL-10-producing Bregs decreased significantly compared to healthy controls, and this decrease was more pronounced in nonsurvivors than in survivors [73]. Moreover, a transient depletion of memory B cells and Bregs from the circulation was observed in experimental endotoxemia in humans [74].

Bregs may exert a protective effect through their anti-inflammatory function in sepsis. It has been noted that the expression of IL-10 in CD5⁺CD1d^{hi} Bregs was remarkably reduced in severe septic shock mice in response to endotoxin. In addition, the adoptive transfer of CD5⁺CD1d^{hi} Bregs from healthy WT mice (but not from IL-10-deficient mice) led to the downregulation of IFN- γ secretion in CD4⁺ T cells, protecting against endotoxic shock. This highlights the significant therapeutic potential of IL-10-producing Bregs in mitigating endotoxic shock [72]. Furthermore, research has shown that IL-35-expressing B cells can regulate Th17 cell function and suppress inflammation. Injection of recombinant IL-35 or IL-35p Bregs into mice has been observed to resolve inflammation by suppressing effector Th1 and Th17 cell responses while simultaneously regulating Treg-cell responses [75, 76].

The changes in Bregs observed in sepsis suggest a potential role for Bregs in the pathogenesis and outcome of sepsis. The reduction and functional impairment of Bregs may contribute to excessive and dysregulated inflammation in sepsis, leading to poor prognosis.

5. Alterations of Circulating B-Cell Counts in Patients with Sepsis

Reduced lymphocyte counts are closely associated with immunosuppression in sepsis and the prognosis [21]. The numbers of B cells and their subsets decline in sepsis but remain debatable. For instance, some studies have reported a decrease in the total number of B cells in the peripheral blood [77, 78], but their counts did not significantly change

in other cases [46]. Peripheral blood samples are most analyzed in studies on B cells of patients with sepsis. Table 1 and Table S1 highlight findings from studies on peripheral blood B cells.

Table 1 includes studies that quantified changes in peripheral blood B-cell counts in patients with sepsis. Two meta-analyses reported changes in the overall count of circulating B cells within 24 hr of onset, but their results did not exactly match because different studies were included [19, 20]. Both reported that circulating B-cell counts in dead patients were significantly lower than in surviving patients, suggesting that B-cell counts are closely related to patient prognosis, which was confirmed in other studies [16, 48]. However, comparisons of patients with healthy controls were inconsistent: one meta-analysis showed no significant difference in circulating B-cell counts between patients and controls [19], while the other reported significantly fewer B cells in patients than in controls [20]. The latter was supported by three other studies [16, 79, 80], and similar results were obtained at other time points (48 hr after admission and days 3, 4, 7, and 8 after onset) [16, 77–80]. Ultimately, most studies indicate lower peripheral blood B-cell counts in patients with sepsis, which is closely related to prognosis. An experimental human endotoxemia model also supports this conclusion [74]. Besides, another study found that the splenic B-cell counts of patients with sepsis were significantly reduced compared with traumatic or critically ill patients without sepsis—greater B-cell loss was linked to persistent sepsis [81].

Table S1 includes studies that monitored how the counts or percentage of peripheral blood B-cell subsets change in patients with sepsis. The selected B-cell subsets and their definitions varied across studies. Results differed even for naïve B cells with relatively uniform nomenclature and surface markers: two studies reported a lower percentage of naïve B cells in patients than in controls [46, 80], and one study found no significant difference in percentages between patients and controls [78], and one study reported a higher percentage in patients than in controls [79]. These studies offer some valuable insights despite their inconsistencies. For example, sepsis indeed affects the B-cell compartment, whose different subsets are uniquely affected. Therefore, future studies should address the subsets separately rather than describing B cells as a whole.

B-cell counts decrease due to a decrease in the source, increased exhaustion, or both. Studies have shown that B-cell depletion is not due to impaired bone marrow production [48, 77] but rather apoptosis [4, 79]. The activation of B cells in patients with sepsis is unsustainable and accelerates apoptosis [79, 80], as shown by a mouse model of sepsis [82, 83]. B cells in humanized mice also show characteristic signs of apoptosis observed in human patients with sepsis [84]. Sensitivity to apoptosis may differ across subtypes, and highly sensitive memory B cells may experience more severe apoptosis [85]. The pathways of B-cell apoptosis are also diverse, including endogenous and exogenous apoptosis [86]. Additionally, patients with sepsis have fewer antigen-presenting T cells in their secondary lymphoid organs, which may impair B-cell maturation and deplete B cells [81, 87, 88]. Besides, circulating

TABLE 1: Changes in circulating B-cell counts in patients with sepsis/septic shock.

Reference	Year	Design/sample size	Blood collection time	Results
[16]	2020	Prospective cohort study; survivors ($n = 57$), nonsurvivors ($n = 24$), healthy controls ($n = 13$)	Days 1, 3, and 7 of septic shock onset.	On days 1, 3, and 7, B-cell counts were lower in patients than in healthy controls; on day 7, it was lower in nonsurvivors than in survivors
[19]	2019	Meta-analysis; seven studies* (1999–2017) were included, and sample sizes ranged from 21 to 181	Within 24 hr of sepsis/septic shock onset	There was no significant difference in B-cell counts between patients and healthy controls, but lower in nonsurvivors than in survivors
[20]	2018	Meta-analysis; seven studies* (1999–2013) were included, and sample sizes ranged from 21 to 291	Within 24 hr of sepsis/septic shock onset	B-cell counts were lower in patients than in healthy controls and were lower in nonsurvivors than in survivors
[48]	2020	Prospective cohort study; survivors ($n = 23$), nonsurvivors ($n = 17$)	Within and after 24 hr of sepsis onset	At both time points, B-cell counts were lower in nonsurvivors than in survivors
[77]	2019	Prospective cohort study; ICU patients ($n = 105$, sepsis ($n = 52$), nonsepsis ($n = 53$)), healthy controls ($n = 63$)	At the time of ICU admission and 48 hr after admission	At both time points, B-cell counts in ICU patients were lower than those in healthy controls; there was a decreasing trend in the sepsis group compared with the nonsepsis group, but there was no significant difference
[78]	2018	Prospective cohort study; patients ($n = 138$)	Day 3 of septic shock onset	B-cell counts in patients were lower than the clinical laboratory age-matched reference value
[79]	2017	Prospective cohort study; patients with septic shock ($n = 24$)	Days 1 and 7 of septic shock onset	At both time points, the B-cell counts in patients with sepsis were lower than the population median
[80]	2020	Prospective cohort study; patients with sepsis ($n = 10$), healthy controls ($n = 10$)	Days 1, 4, and 8 of sepsis onset	At all three time points, the relative percentage of B cells in patients was lower than in healthy controls

*The studies involved in meta-analysis are no longer discussed separately. ICU, intensive care unit.

B-cell counts may also decrease because B cells flock to the site of inflammation during infection.

6. Changes of B-Cell Functions in Patients with Sepsis

The B cells in patients with sepsis not only change in numbers but also functions (Figure 2). The main function of B cells is to secrete a variety of antibodies to eliminate pathogens. Patients with sepsis show abnormal serum immunoglobulin levels, which indicate high mortality [89, 90]. Levels of various immunoglobulin subtypes can also change in patients with sepsis. One study found that 16 of 21 patients with septic shock developed hypoglobulinemia, where levels of IgG and/or IgM decreased [91]. Another study reported that levels of IgG, IgM, and IgA decreased in 61%, 40%, and 4% of 62 patients with septic shock, respectively [89]. This means the level of any immunoglobulin subtype decreases in a patient-specific way, and not every type will decrease in a single patient. Overall levels of IgM decreased in the sepsis patient group when compared to healthy controls, whereas the IgG and IgA levels do not significantly differ. This result has been further verified in vitro [16, 47]. Decreased IgM levels were also found in a larger study that included 332 patients. Here, IgM levels were

significantly lower in patients with sepsis or septic shock compared with healthy controls and were significantly higher in survivors than in nonsurvivors [92]. Furthermore, two meta-analyses invariably reported decreased IgM levels within 24 hr in patients with sepsis, which was associated with reduced survival [19, 20]. Overall, decreased levels of IgM are widely implicated in patients with sepsis and poor prognosis.

CD27⁺ B cells are the main antibody-secreting cells, and CD27⁺CD21^{hi} B cells have a stronger IgM-producing capacity than CD27⁺CD21^{lo} B cells [93, 94]. Our recent study found no significant difference in the expression levels of IgM on the surface of B-cell subsets between patients with septic shock and healthy controls, indicating that IgM levels decreased not because of immunoglobulin class switching. Moreover, the IgM levels positively correlated with the number of CD27⁺CD21^{hi} resting memory B cells in patients with septic shock [16]. Therefore, their decrease could be attributed to the depletion of resting memory B cells. Impaired immunoglobulin assembly may also contribute [95]: the heavy and light chains of immunoglobulins are produced and assembled in B cells or plasma cells, and when more light chains than heavy chains are produced intracellularly, the excess light chains are released into the blood. Abnormally elevated concentrations of circulating light chains (free κ and λ




FIGURE 2: Changes of circulating B cells in patients with sepsis. Significant alterations in both the counts and function of circulating B cells were observed in patients suffering from sepsis.

chains) have been observed in patients with sepsis, suggesting impaired immunoglobulin assembly [96, 97]. Furthermore, any given immunoglobulin normally has either two light chains κ or λ : mature B cells produce only one class of Ig light chains [98, 99]. However, B cells with both light-chain κ and λ emerged in the blood of patients with sepsis, and higher numbers of B cells expressing both light-chain κ and λ were positively correlated with free light-chain κ and λ levels [95].

Several other B-cell functions change in sepsis. For example, during sepsis, the expression levels of human leukocyte antigen-DR decrease in B cells, and the expression levels of PD-1, PD-L1, CD95, and CD80 increase. These phenotypic changes may not only impair the ability of B cells to present antigens but also affect prognosis [80, 100, 101]. Furthermore, the activation and proliferation of circulating B cells in patients with sepsis decrease and tend to failure [102, 103]. Besides, B cells in septic mice abnormally secrete cytokines, resulting in insufficient innate immune response and increased mortality [18]. Overall, these multifaceted changes in B-cell functions do not occur independently and likely affect each other. Altered functions may further deplete B-cell counts and vice-versa to promote immunosuppression in patients with sepsis.

7. B-Cell-Related Immunotherapy in Sepsis

B-cell-related immunotherapies for sepsis focus on replenishing the numbers and functions of B cells. Apoptosis exhausts many immune cells, including B cells, and likely contributes to sepsis-induced immunosuppression, and its extent relates to the severity and prognosis [104, 105]. As mentioned earlier, B cells in sepsis show increased expression of CD95 and PD-1. Down-regulating their expression or blocking their binding

to ligands may improve the survival rate of septic mice [106–110]. Another strategy includes treatment with anti-CD40, IL-15, or IL-30 to upregulate the expression of anti-apoptotic protein Bcl-2 in B cells [109, 111–113]. Caspase-3 is a key enzyme whose activation is a prerequisite to endogenous and exogenous apoptotic pathways; inhibition of its activity has been shown to enhance the survival of septic mice [114–116]. Besides, B cells can also be recovered in septic mice by inhibiting caspase-1, a protein that mediates pyroptosis. Therefore, inhibiting pyroptosis may also be promising [117–119]. Besides, hematopoietic stem cell (HSC) rejuvenation therapies, such as FOXOs and CASIN, could contribute to the regulation of cell growth and survival, increase the pools of common lymphoid progenitor cells, and restore the B-cell counts in the body. This indicates that similar therapies and drugs for HSC rejuvenation could be a promising strategy for restoring B-cell loss [120, 121]. Moreover, animal studies have shown that supplementing specific B-cell subsets through immunotherapy, such as introducing B-1a cells or CD5⁺CD1d^{hi} Bregs, can efficiently reduce inflammatory reactions and prevent organ damage. These results suggest that immunotherapy to reverse B-cell depletion can reduce the harm caused by sepsis [55, 57].

Immunoglobulin supplementation can compensate for the reduced secretion of antibodies by B cells in patients with sepsis. IgG is the main antibody component in serum and body fluids, accounting for about 80% of the total serum immunoglobulin. Although intravenous IgG-only polyclonal immunoglobulin has been suggested to treat sepsis, it has not been proven beneficial [119, 122], even in a large study ($n = 624$) [123]. Polyclonal immunoglobulins could also be supplemented because they are rich in IgM and IgA

(IgGAM). A meta-analysis of 19 trials involving more than 1,500 patients with sepsis evaluated the efficacy of IgGAM and found that it significantly reduced mortality [124]. IgGAM therapy has also improved outcomes of patients with sepsis across studies [125, 126]. However, the efficacy of IgGAM must be further verified in larger clinical studies.

It is important to be vigilant about the impact of “sepsis heterogeneity” during immunotherapy. As previously mentioned, patients may have been exposed to different pathogenic factors or infected with various microorganisms. Additionally, they may have varying degrees of severity, be at different disease stages, or have different comorbidities. These variables make immunotherapy challenging. Therefore, personalized treatment should be prioritized when conducting immunotherapy.

8. Conclusions

B cells primarily arise in the bone marrow and mature in the periphery. They differentiate into antibody-secreting cells and memory B cells when they encounter antigens. The B1, MZ, and FO B-cell subsets play vital roles in anti-infective immunity and therefore sepsis as well. Bregs have immunomodulatory functions and may play a protective role in sepsis. Most studies report depleted numbers of circulating B cells in patients with sepsis who suffer from poorer prognoses. Different subsets of B cells are not consistently affected across patients, though their general depletion could be to activation-related apoptosis and maturation disorders. Sepsis also impairs B-cell functions. Decreased serum IgM levels are a hallmark of sepsis and poor prognosis. B cells manifest abnormal functions in several ways that could relate to their abnormal counts, and both factors promote immunosuppression. Current promising B-cell-related immunotherapies include reducing depletion or replenishing B cells as well as supplementing with IgGAM. Future studies should pay more attention to B-cell subsets rather than B cells as a whole because sepsis affects the former inconsistently. Finally, immunotherapies for sepsis should prioritize individualization.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Funding

The study was funded by the National Natural Science Foundation of China (No. 82202387).

Supplementary Materials

Table S1: Changes in percentages or counts of circulating B-cell subset in patients with sepsis/septic shock. (*Supplementary Materials*)

References

- [1] M. Singer, C. S. Deutschman, C. W. Seymour et al., “The third international consensus definitions for sepsis and septic shock (Sepsis-3),” *JAMA*, vol. 315, no. 8, pp. 801–810, 2016.
- [2] F. Pei, R.-Q. Yao, C. Ren et al., “Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression,” *Military Medical Research*, vol. 9, Article ID 74, 2022.
- [3] A. C. Liu, K. Patel, R. D. Vunikili et al., “Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses,” *Briefings in Bioinformatics*, vol. 21, no. 4, pp. 1182–1195, 2020.
- [4] F. Venet and G. Monneret, “Advances in the understanding and treatment of sepsis-induced immunosuppression,” *Nature Reviews Nephrology*, vol. 14, pp. 121–137, 2018.
- [5] F. Steinhagen, S. V. Schmidt, J.-C. Schewe, K. Peukert, D. M. Klinman, and C. Bode, “Immunotherapy in sepsis-brake or accelerate?” *Pharmacology & Therapeutics*, vol. 208, Article ID 107476, 2020.
- [6] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and septic shock,” *The Lancet*, vol. 392, no. 10141, pp. 75–87, 2018.
- [7] X. Wang, N. L. Buechler, A. G. Woodruff et al., “Sirtuins and immuno-metabolism of sepsis,” *International Journal of Molecular Sciences*, vol. 19, no. 9, Article ID 2738, 2018.
- [8] G. P. Otto, M. Sossdorf, R. A. Claus et al., “The late phase of sepsis is characterized by an increased microbiological burden and death rate,” *Critical Care*, vol. 15, Article ID R183, 2011.
- [9] L. K. Torres, P. Pickkers, and T. van der Poll, “Sepsis-induced immunosuppression,” *Annual Review of Physiology*, vol. 84, pp. 157–181, 2022.
- [10] D. Liu, S.-Y. Huang, J.-H. Sun et al., “Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options,” *Military Medical Research*, vol. 9, Article ID 56, 2022.
- [11] J. G. Cyster and C. D. C. Allen, “B cell responses: cell interaction dynamics and decisions,” *Cell*, vol. 177, no. 3, pp. 524–540, 2019.
- [12] K. Pieper, B. Grimbacher, and H. Eibel, “B-cell biology and development,” *Journal of Allergy and Clinical Immunology*, vol. 131, no. 4, pp. 959–971, 2013.
- [13] T. Zhu, R. Wang, H. Miller et al., “The interaction between iNKT cells and B cells,” *Journal of Leukocyte Biology*, vol. 111, no. 3, pp. 711–723, 2022.
- [14] N. Imahashi, R. Basar, Y. Huang et al., “Activated B cells suppress T-cell function through metabolic competition,” *Journal for Immunotherapy of Cancer*, vol. 10, no. 12, Article ID e005644, 2022.
- [15] M. D. Taylor, M. R. Brewer, A. Nedeljkovic-Kurepa et al., “CD4 T follicular helper cells prevent depletion of follicular B cells in response to cecal ligation and puncture,” *Frontiers in Immunology*, vol. 11, Article ID 1946, 2020.
- [16] X. Dong, Q. Liu, Q. Zheng et al., “Alterations of B cells in immunosuppressive phase of septic shock patients,” *Critical Care Medicine*, vol. 48, no. 6, pp. 815–821, 2020.
- [17] M. J. Delano and P. A. Ward, “Sepsis-induced immune dysfunction: can immune therapies reduce mortality?” *Journal of Clinical Investigation*, vol. 126, no. 1, pp. 23–31, 2016.
- [18] K. M. Kelly-Scumpia, P. O. Scumpia, J. S. Weinstein et al., “B cells enhance early innate immune responses during bacterial sepsis,” *Journal of Experimental Medicine*, vol. 208, no. 8, pp. 1673–1682, 2011.
- [19] L. Tian, J. Zhu, J. Jin et al., “Prognostic value of circulating lymphocyte B and plasma immunoglobulin M on septic shock and sepsis: a systematic review and meta-analysis,” *American Journal of Translational Research*, vol. 11, no. 12, pp. 7223–7232, 2019.
- [20] C. Krautz, S. L. Maier, M. Brunner et al., “Reduced circulating B cells and plasma IgM levels are associated with decreased

- survival in sepsis—a meta-analysis,” *Journal of Critical Care*, vol. 45, pp. 71–75, 2018.
- [21] X. Dong, C. Wang, X. Liu, W. Gao, X. Bai, and Z. Li, “Lessons learned comparing immune system alterations of bacterial sepsis and SARS-CoV-2 sepsis,” *Frontiers in Immunology*, vol. 11, Article ID 598404, 2020.
 - [22] R. R. Hardy, P. W. Kincade, and K. Dorshkind, “The protean nature of cells in the B lymphocyte lineage,” *Immunity*, vol. 26, no. 6, pp. 703–714, 2007.
 - [23] M. Bulati, C. Caruso, and G. Colonna-Romano, “From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by “inflamm-aging,”” *Ageing Research Reviews*, vol. 36, pp. 125–136, 2017.
 - [24] L. Ionescu and S. Urschel, “Memory B cells and long-lived plasma cells,” *Transplantation*, vol. 103, no. 5, pp. 890–898, 2019.
 - [25] Z. Hua and B. Hou, “TLR signaling in B-cell development and activation,” *Cellular & Molecular Immunology*, vol. 10, pp. 103–106, 2013.
 - [26] V. G. Martin, Y.-C. B. Wu, C. L. Townsend et al., “Transitional B cells in early human B cell development—time to revisit the paradigm?” *Frontiers in Immunology*, vol. 7, Article ID 546, 2016.
 - [27] J. J. Sabatino Jr., A.-K. Pröbstel, and S. S. Zamvil, “B cells in autoimmune and neurodegenerative central nervous system diseases,” *Nature Reviews Neuroscience*, vol. 20, pp. 728–745, 2019.
 - [28] M. Perez-Andres, B. Paiva, W. G. Nieto et al., “Human peripheral blood B-cell compartments: a crossroad in B-cell traffic,” *Cytometry Part B: Clinical Cytometry*, vol. 78B, no. S1, pp. S47–S60, 2010.
 - [29] C. Ma, H. Liu, S. Yang, H. Li, X. Liao, and Y. Kang, “The emerging roles and therapeutic potential of B cells in sepsis,” *Frontiers in Pharmacology*, vol. 13, Article ID 1034667, 2022.
 - [30] W. Hoffman, F. G. Lakkis, and G. Chalasani, “B Cells, antibodies, and more,” *Clinical Journal of the American Society of Nephrology*, vol. 11, no. 1, pp. 137–154, 2016.
 - [31] A. Cerutti, M. Cols, and I. Puga, “Activation of B cells by non-canonical helper signals,” *EMBO reports*, vol. 13, pp. 798–810, 2012.
 - [32] S. Hillion, M. I. Arleevskaya, P. Blanco et al., “The innate part of the adaptive immune system,” *Clinical Reviews in Allergy & Immunology*, vol. 58, pp. 151–154, 2020.
 - [33] C. H. D. Barbosa, L. Lantier, J. Reynolds, J. Wang, and F. Re, “Critical role of IL-25-ILC2-IL-5 axis in the production of anti-Francisella LPS IgM by B1 B cells,” *PLOS Pathogens*, vol. 17, no. 8, Article ID e1009905, 2021.
 - [34] L. Liu, J. Zhao, A. Li, X. Yang, B. Sprangers, and S. Li, “Artemisinin attenuates IgM xenoantibody production via inhibition of T cell-independent marginal zone B cell proliferation,” *Journal of Leukocyte Biology*, vol. 109, no. 3, pp. 583–591, 2021.
 - [35] L.-W. Lo, C.-W. Chang, M.-F. Chiang, I.-Y. Lin, and K.-I. Lin, “Marginal zone B cells assist with neutrophil accumulation to fight against systemic *Staphylococcus aureus* infection,” *Frontiers in Immunology*, vol. 12, Article ID 636818, 2021.
 - [36] R. R. Reid, A. P. Prodeus, W. Khan, T. Hsu, F. S. Rosen, and M. C. Carroll, “Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide,” *The Journal of Immunology*, vol. 159, no. 2, pp. 970–975, 1997.
 - [37] G. D. Victora and M. C. Nussenzweig, “Germinal centers,” *Annual Review of Immunology*, vol. 40, pp. 413–442, 2022.
 - [38] M. J. Shlomchik and F. Weisel, “Germinal center selection and the development of memory B and plasma cells,” *Immunological Reviews*, vol. 247, no. 1, pp. 52–63, 2012.
 - [39] G. D. Victora and M. C. Nussenzweig, “Germinal centers,” *Annual Review of Immunology*, vol. 30, no. 1, pp. 429–457, 2012.
 - [40] T. Kurosaki, K. Kometani, and W. Ise, “Memory B cells,” *Nature Reviews Immunology*, vol. 15, pp. 149–159, 2015.
 - [41] M. D. Taylor, M. R. Brewer, and C. S. Deutschman, “Induction of diverse T cell memory through antibody-mediated activation in mice,” *European Journal of Immunology*, vol. 50, no. 11, pp. 1838–1840, 2020.
 - [42] J. S. Turner, W. Kim, E. Kalaidina et al., “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans,” *Nature*, vol. 595, pp. 421–425, 2021.
 - [43] C. Markmann and V. G. Bhoj, “On the road to eliminating long-lived plasma cells—“are we there yet?”,” *Immunological Reviews*, vol. 303, no. 1, pp. 154–167, 2021.
 - [44] F. Capolunghi, M. M. Rosado, M. Sinibaldi, A. Aranburu, and R. Carsetti, “Why do we need IgM memory B cells?” *Immunology Letters*, vol. 152, no. 2, pp. 114–120, 2013.
 - [45] M. P. Cancro and M. M. Tomayko, “Memory B cells and plasma cells: the differentiative continuum of humoral immunity,” *Immunological Reviews*, vol. 303, no. 1, pp. 72–82, 2021.
 - [46] S. J. Jeong, S. S. Yoon, S. H. Han, D. E. Yong, C. O. Kim, and J. M. Kim, “Evaluation of humoral immune response to nosocomial pathogen and functional status in elderly patients with sepsis,” *Archives of Gerontology and Geriatrics*, vol. 58, no. 1, pp. 10–14, 2014.
 - [47] K. Suzuki, S. Inoue, Y. Kametani et al., “Reduced immunocompetent B cells and increased secondary infection in elderly patients with severe sepsis,” *Shock*, vol. 46, no. 3, pp. 270–278, 2016.
 - [48] S. Duan, Y. Jiao, J. Wang et al., “Impaired B-cell maturation contributes to reduced B cell numbers and poor prognosis in sepsis,” *Shock*, vol. 54, no. 1, pp. 70–77, 2020.
 - [49] C. Cao, M. Yu, and Y. Chai, “Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis,” *Cell Death & Disease*, vol. 10, Article ID 782, 2019.
 - [50] S. Fagarasan, S. Kawamoto, O. Kanagawa, and K. Suzuki, “Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis,” *Annual Review of Immunology*, vol. 28, pp. 243–273, 2010.
 - [51] F. L. Smith and N. Baumgarth, “B-1 cell responses to infections,” *Current Opinion in Immunology*, vol. 57, pp. 23–31, 2019.
 - [52] A. F. Cunningham, A. Flores-Langarica, S. Bobat et al., “B1b cells recognize protective antigens after natural infection and vaccination,” *Frontiers in Immunology*, vol. 5, Article ID 535, 2014.
 - [53] K. M. Haas, “B-1 lymphocytes in mice and nonhuman primates,” *Annals of the New York Academy of Sciences*, vol. 1362, no. 1, pp. 98–109, 2015.
 - [54] M. Aziz, N. E. Holodick, T. L. Rothstein, and P. Wang, “The role of B-1 cells in inflammation,” *Immunologic Research*, vol. 63, pp. 153–166, 2015.
 - [55] M. Aziz, N. E. Holodick, T. L. Rothstein, and P. Wang, “B-1a cells protect mice from sepsis: critical role of CREB,” *The Journal of Immunology*, vol. 199, no. 2, pp. 750–760, 2017.

- [56] P. J. Rauch, A. Chudnovskiy, C. S. Robbins et al., "Innate response activator B cells protect against microbial sepsis," *Science*, vol. 335, no. 6068, pp. 597–601, 2012.
- [57] M. Aziz, Y. Ode, M. Zhou et al., "B-1a cells protect mice from sepsis-induced acute lung injury," *Molecular Medicine*, vol. 24, Article ID 26, 2018.
- [58] S. Pillai, A. Cariappa, and S. T. Moran, "Marginal zone B cells," *Annual Review of Immunology*, vol. 23, pp. 161–196, 2005.
- [59] A.-K. E. Palm and S. Kleinau, "Marginal zone B cells: from housekeeping function to autoimmunity?" *Journal of Autoimmunity*, vol. 119, Article ID 102627, 2021.
- [60] R. Guinamard, M. Okigaki, J. Schlessinger, and J. V. Ravetch, "Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response," *Nature Immunology*, vol. 1, pp. 31–36, 2000.
- [61] K. Tanigaki, H. Han, N. Yamamoto et al., "Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells," *Nature Immunology*, vol. 3, pp. 443–450, 2002.
- [62] A. Cerutti, M. Cols, and I. Puga, "Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes," *Nature Reviews Immunology*, vol. 13, pp. 118–132, 2013.
- [63] T. Lopes-Carvalho, J. Foote, and J. F. Kearney, "Marginal zone B cells in lymphocyte activation and regulation," *Current Opinion in Immunology*, vol. 17, no. 3, pp. 244–250, 2005.
- [64] S.-I. Honda, K. Sato, N. Totsuka et al., "Marginal zone B cells exacerbate endotoxic shock via interleukin-6 secretion induced by Fc α / μ R-coupled TLR4 signalling," *Nature Communications*, vol. 7, Article ID 11498, 2016.
- [65] L. McCulloch, C. J. Smith, and B. W. McColl, "Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke," *Nature Communications*, vol. 8, Article ID 15051, 2017.
- [66] A. Shibuya, S.-I. Honda, and K. Shibuya, "A pro-inflammatory role of Fc α / μ R on marginal zone B cells in sepsis," *International Immunology*, vol. 29, no. 11, pp. 519–524, 2017.
- [67] J. C. Weill, S. Weller, and C.-A. Reynaud, "Human marginal zone B cells," *Annual Review of Immunology*, vol. 27, pp. 267–285, 2009.
- [68] C.-C. Lee and J. T. Kung, "Marginal zone B cell is a major source of IL-10 in *Listeria monocytogenes* susceptibility," *The Journal of Immunology*, vol. 189, no. 7, pp. 3319–3327, 2012.
- [69] E. C. Rosser and C. Mauri, "Regulatory B cells: origin, phenotype, and function," *Immunity*, vol. 42, no. 4, pp. 607–612, 2015.
- [70] K. Jansen, L. Cevhertas, S. Ma, P. Satitsuksanoa, M. Akdis, and W. van de Veen, "Regulatory B cells, A to Z," *Allergy*, vol. 76, no. 9, pp. 2699–2715, 2021.
- [71] K. Umakoshi, M. E. Choudhury, R. Nishioka et al., "B lymphocytopenia and Bregs in a not-to-die murine sepsis model," *Biochemical and Biophysical Research Communications*, vol. 523, no. 1, pp. 202–207, 2020.
- [72] L. Tao, Y. Wang, J. Xu et al., "IL-10-producing regulatory B cells exhibit functional defects and play a protective role in severe endotoxic shock," *Pharmacological Research*, vol. 148, Article ID 104457, 2019.
- [73] C. Wang, H. Xu, R. Gao et al., "CD19⁺CD24^{hi}CD38^{hi} regulatory B cells deficiency revealed severity and poor prognosis in patients with sepsis," *BMC Immunology*, vol. 23, Article ID 54, 2022.
- [74] A. Brinkhoff, Y. Zeng, A. Sieberichs et al., "B-cell dynamics during experimental endotoxemia in humans," *Bioscience Reports*, vol. 39, no. 5, Article ID BSR20182347, 2019.
- [75] P. Shen, T. Roch, V. Lampropoulou et al., "IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases," *Nature*, vol. 507, pp. 366–370, 2014.
- [76] R.-X. Wang, C.-R. Yu, I. M. Dambuza et al., "Interleukin-35 induces regulatory B cells that suppress autoimmune disease," *Nature Medicine*, vol. 20, pp. 633–641, 2014.
- [77] P. Hohlstein, H. Gussen, M. Bartneck et al., "Prognostic relevance of altered lymphocyte subpopulations in critical illness and sepsis," *Journal of Clinical Medicine*, vol. 8, no. 3, Article ID 353, 2019.
- [78] C.-A. Gustave, M. Gossez, J. Demaret et al., "Septic shock shapes B Cell response toward an exhausted-like/immunoregulatory profile in patients," *The Journal of Immunology*, vol. 200, no. 7, pp. 2418–2425, 2018.
- [79] M. Shankar-Hari, D. Fear, P. Lavender et al., "Activation-associated accelerated apoptosis of memory B cells in critically ill patients with sepsis," *Critical Care Medicine*, vol. 45, no. 5, pp. 875–882, 2017.
- [80] J. Schenz, S. Tamulyte, C. Nussbag et al., "Population-specific metabolic alterations in professional antigen-presenting cells contribute to sepsis-associated immunosuppression," *Shock*, vol. 53, no. 1, pp. 5–15, 2020.
- [81] R. S. Hotchkiss, K. W. Tinsley, P. E. Swanson et al., "Sepsis-induced apoptosis causes progressive profound depletion of B and CD4⁺ T lymphocytes in humans," *The Journal of Immunology*, vol. 166, no. 11, pp. 6952–6963, 2001.
- [82] K. Schmoeckel, D. M. Mrochen, J. Hühn, C. Pötschke, and B. M. Bröker, "Polymicrobial sepsis and non-specific immunization induce adaptive immunosuppression to a similar degree," *PLOS ONE*, vol. 13, no. 2, Article ID e0192197, 2018.
- [83] A. Mohr, J. Polz, E. M. Martin et al., "Sepsis leads to a reduced antigen-specific primary antibody response," *European Journal of Immunology*, vol. 42, no. 2, pp. 341–352, 2012.
- [84] J. Unsinger, J. S. McDonough, L. D. Shultz, T. A. Ferguson, and R. S. Hotchkiss, "Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice," *Journal of Leukocyte Biology*, vol. 86, no. 2, pp. 219–227, 2009.
- [85] U. Klein, Y. Tu, G. A. Stolovitzky et al., "Transcriptional analysis of the B cell germinal center reaction," *Proceedings of the National Academy of Sciences*, vol. 100, no. 5, pp. 2639–2644, 2003.
- [86] K. C. Chang, J. Unsinger, C. G. Davis et al., "Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis," *The FASEB Journal*, vol. 21, no. 3, pp. 708–719, 2007.
- [87] J. S. Boomer, K. To, K. C. Chang et al., "Immunosuppression in patients who die of sepsis and multiple organ failure," *JAMA*, vol. 306, no. 23, pp. 2594–2605, 2011.
- [88] F. Venet, A.-C. Lukaszewicz, D. Payen, R. Hotchkiss, and G. Monneret, "Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies," *Current Opinion in Immunology*, vol. 25, no. 4, pp. 477–483, 2013.
- [89] F. Venet, R. Gebele, J. Bancel et al., "Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients," *International Immunopharmacology*, vol. 11, no. 12, pp. 2086–2090, 2011.
- [90] J. F. Bermejo-Martín, A. Rodríguez-Fernández, R. Herrán-Monge et al., "Immunoglobulins IgG1, IgM and IgA: a

- synergistic team influencing survival in sepsis,” *Journal of Internal Medicine*, vol. 276, no. 4, pp. 404–412, 2014.
- [91] P. M. Myrianthefs, E. Boutzouka, and G. J. Baltopoulos, “ γ -globulin levels in patients with community-acquired septic shock,” *Shock*, vol. 33, no. 5, pp. 556–557, 2010.
 - [92] E. J. Giamarellos-Bourboulis, E. Apostolidou, M. Lada et al., “Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome,” *Critical Care*, vol. 17, Article ID R247, 2013.
 - [93] A. Das, H. Xu, X. Wang, C. L. Yau, R. S. Veazey, and B. Pahar, “Double-positive CD21⁺CD27⁺ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues,” *PLOS ONE*, vol. 6, no. 1, Article ID e16524, 2011.
 - [94] E. D. Charles, C. Brunetti, S. Marukian et al., “Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21^{low} B-cell subset,” *Blood*, vol. 117, no. 20, pp. 5425–5437, 2011.
 - [95] M. Shankar-Hari, M. Singer, and J. Spencer, “Can concurrent abnormalities in free light chains and immunoglobulin concentrations identify a target population for immunoglobulin trials in sepsis?,” *Critical Care Medicine*, vol. 45, no. 11, pp. 1829–1836, 2017.
 - [96] F. S. Taccone, P. Stordeur, D. De Backer, J. Creteur, and J.-L. Vincent, “ γ -Globulin levels in patients with community-acquired septic shock,” *Shock*, vol. 32, no. 4, pp. 379–385, 2009.
 - [97] A. Dispenzieri, J. A. Katzmman, R. A. Kyle et al., “Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population,” *Mayo Clinic Proceedings*, vol. 87, no. 6, pp. 517–523, 2012.
 - [98] C. Vettermann and M. S. Schlissel, “Allelic exclusion of immunoglobulin genes: models and mechanisms,” *Immunological Reviews*, vol. 237, no. 1, pp. 22–42, 2010.
 - [99] D. Xu, “Dual surface immunoglobulin light-chain expression in B-cell lymphoproliferative disorders,” *Archives of Pathology & Laboratory Medicine*, vol. 130, no. 6, pp. 853–856, 2006.
 - [100] J. Monserrat, R. de Pablo, D. Diaz-Martín et al., “Early alterations of B cells in patients with septic shock,” *Critical Care*, vol. 17, Article ID R105, 2013.
 - [101] J. K. Wilson, Y. Zhao, M. Singer, J. Spencer, and M. Shankar-Hari, “Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis-pilot study,” *Critical Care*, vol. 22, Article ID 95, 2018.
 - [102] E. E. Davenport, K. L. Burnham, J. Radhakrishnan et al., “Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study,” *The Lancet Respiratory Medicine*, vol. 4, no. 4, pp. 259–271, 2016.
 - [103] R. de Pablo, J. Monserrat, A. Prieto, and M. Alvarez-Mon, “Role of circulating lymphocytes in patients with sepsis,” *BioMed Research International*, vol. 2014, Article ID 671087, 11 pages, 2014.
 - [104] T. Girardot, T. Rimmelé, F. Venet, and G. Monneret, “Apoptosis-induced lymphopenia in sepsis and other severe injuries,” *Apoptosis*, vol. 22, pp. 295–305, 2017.
 - [105] J. D. Lang and G. Matute-Bello, “Lymphocytes, apoptosis and sepsis: making the jump from mice to humans,” *Critical Care*, vol. 13, Article ID 109, 2009.
 - [106] X. Huang, F. Venet, Y. L. Wang et al., “PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis,” *Proceedings of the National Academy of Sciences*, vol. 106, no. 15, pp. 6303–6308, 2009.
 - [107] N. Matsuda, S. Yamamoto, K.-I. Takano et al., “Silencing of fas-associated death domain protects mice from septic lung inflammation and apoptosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 179, no. 9, pp. 806–815, 2009.
 - [108] C.-S. Chung, W. Wang, I. H. Chaudry, and A. Ayala, “Increased apoptosis in lamina propria B cells during polymicrobial sepsis is FasL but not endotoxin mediated,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 280, no. 5, pp. G812–G818, 2001.
 - [109] S. Li, F.-X. Zhu, X.-J. Zhao, and Y.-Z. An, “The immunoprotective activity of interleukin-33 in mouse model of cecal ligation and puncture-induced sepsis,” *Immunology Letters*, vol. 169, pp. 1–7, 2016.
 - [110] Y.-M. Hu, Y.-C. Hsiung, M.-H. Pai, and S.-L. Yeh, “Glutamine administration in early or late septic phase downregulates lymphocyte PD-1/PD-L1 expression and the inflammatory response in mice with polymicrobial sepsis,” *Journal of Parenteral and Enteral Nutrition*, vol. 42, no. 3, pp. 538–549, 2018.
 - [111] S. J. Schwulst, M. H. Grayson, P. J. DiPasco et al., “Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis,” *The Journal of Immunology*, vol. 177, no. 1, pp. 557–565, 2006.
 - [112] S. Inoue, J. Unsinger, C. G. Davis et al., “IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis,” *The Journal of Immunology*, vol. 184, no. 3, pp. 1401–1409, 2010.
 - [113] R. S. Hotchkiss, P. E. Swanson, C. M. Knudson et al., “Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis,” *The Journal of Immunology*, vol. 162, no. 7, pp. 4148–4156, 1999.
 - [114] R. S. Hotchkiss, K. C. Chang, P. E. Swanson et al., “Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte,” *Nature Immunology*, vol. 1, pp. 496–501, 2000.
 - [115] J. Ying, J. Wu, Y. Zhang et al., “Ligustrazine suppresses renal NMDAR1 and caspase-3 expressions in a mouse model of sepsis-associated acute kidney injury,” *Molecular and Cellular Biochemistry*, vol. 464, pp. 73–81, 2020.
 - [116] X. Li, M. Jamal, P. Guo et al., “Irisin alleviates pulmonary epithelial barrier dysfunction in sepsis-induced acute lung injury via activation of AMPK/SIRT1 pathways,” *Biomedicine & Pharmacotherapy*, vol. 118, Article ID 109363, 2019.
 - [117] A. Sarkar, M. W. Hall, M. Exline et al., “Caspase-1 regulates *Escherichia coli* sepsis and splenic B cell apoptosis independently of interleukin-1 β and interleukin-18,” *American Journal of Respiratory and Critical Care Medicine*, vol. 174, no. 9, pp. 1003–1010, 2006.
 - [118] R. A. Aglietti and E. C. Dueber, “Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions,” *Trends in Immunology*, vol. 38, no. 4, pp. 261–271, 2017.
 - [119] Y. He, R. Xu, B. Zhai, S. Zhou, X. Wang, and R. Wang, “Gm614 protects germinal center B cells from death by suppressing caspase-1 transcription in lupus-prone mice,” *Frontiers in Immunology*, vol. 11, Article ID 585726, 2020.
 - [120] S. Akunuru and H. Geiger, “Aging, clonality, and rejuvenation of hematopoietic stem cells,” *Trends in Molecular Medicine*, vol. 22, no. 8, pp. 701–712, 2016.
 - [121] J. de Mol, J. Kuiper, D. Tsiantoulas, and A. C. Foks, “The dynamics of B cell aging in health and disease,” *Frontiers in Immunology*, vol. 12, Article ID 733566, 2021.
 - [122] R. Almansa, E. Tamayo, D. Andaluz-Ojeda et al., “The original sins of clinical trials with intravenous immunoglobulins in sepsis,” *Critical Care*, vol. 19, Article ID 90, 2015.

- [123] Y. M. Arabi, O. C. Dabbagh, H. M. Tamim et al., "Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients," *Critical Care Medicine*, vol. 36, no. 12, pp. 3190–3197, 2008.
- [124] J. Cui, X. Wei, H. Lv et al., "The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis," *Annals of Intensive Care*, vol. 9, Article ID 27, 2019.
- [125] J.-I. Martinez, H.-F. Sánchez, J.-A. Velandia et al., "Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis," *Journal of Critical Care*, vol. 64, pp. 120–124, 2021.
- [126] E. J. Giamarellos-Bourboulis, N. Tziolos, C. Routsis et al., "Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins," *Clinical Microbiology and Infection*, vol. 22, no. 6, pp. 499–506, 2016.